Highlights from Recent Cancer Literature

Abstract

Breaking Insights| August 16 2022 Highlights from Recent Cancer Literature Author & Article Information Online ISSN: 1538-7445 Print ISSN: 0008-5472 ©2022 American Association for Cancer Research2022American Association for Cancer Research Cancer Res (2022) 82 (16): 2809–2810. https://doi.org/10.1158/0008-5472.CAN-82-16-BI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record August 16 2022 Citation Highlights from Recent Cancer Literature. Cancer Res 15 August 2022; 82 (16): 2809–2810. https://doi.org/10.1158/0008-5472.CAN-82-16-BI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Although recurrent genetic alterations in coding regions have been well characterized in diffuse large B-cell lymphoma (DLBCL), these alterations alone appear to be insufficient to drive lymphomagenesis. Bal and colleagues have now uncovered recurrent mutations in noncoding regions in super-enhancers, leading to loss of transcriptional repression of oncogenes, resulting in tumorigenesis. These recurrent mutations share an activation-induced cytidine deaminase signature implicating activation-induced cytidine deaminase as the mutational driver. CRISPR–Cas9-mediated reversion of these mutations led to a significant decrease in oncogene expression and prevented proliferation and survival of DLBCL cell lines. Expert Commentary: This study has uncovered a previously unrecognized role for activation-induced cytidine deaminase-mediated hypermutation of super-enhancers in lymphomagenesis and suggests potential new drug targets in DLBCL. Bal E, Kumar R, Hadigol M, Holmes AB, Hilton LK, Loh JW, et al. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Nature; Published online July 6, 2022; doi: 10.1038/s41586-022-04906-8. Clear... You do not currently have access to this content.